AxoGen FY2025 EPS Estimate Reduced by Cantor Fitzgerald

AxoGen, Inc. (NASDAQ:AXGN - Free Report) - Research analysts at Cantor Fitzgerald dropped their FY2025 earnings estimates for AxoGen in a research report issued on Monday, May 12th. Cantor Fitzgerald analyst R. Osborn now expects that the medical equipment provider will post earnings per share of $0.02 for the year, down from their previous estimate of $0.07. Cantor Fitzgerald currently has a "Overweight" rating and a $24.00 target price on the stock. The consensus estimate for AxoGen's current full-year earnings is ($0.29) per share.

Several other brokerages have also weighed in on AXGN. Canaccord Genuity Group lifted their price objective on AxoGen from $22.00 to $26.00 and gave the stock a "buy" rating in a report on Wednesday, February 26th. Lake Street Capital assumed coverage on shares of AxoGen in a research report on Monday, March 17th. They set a "buy" rating and a $30.00 target price on the stock. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $22.60.

AxoGen Stock Performance

NASDAQ:AXGN opened at $11.39 on Tuesday. The firm's 50-day moving average is $16.61 and its 200-day moving average is $16.32. The company has a market cap of $518.64 million, a price-to-earnings ratio of -35.59 and a beta of 1.19. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.47 and a current ratio of 3.74. AxoGen has a 52-week low of $5.65 and a 52-week high of $21.00.

Hedge Funds Weigh In On AxoGen

Several large investors have recently bought and sold shares of AXGN. R Squared Ltd acquired a new position in shares of AxoGen during the 4th quarter worth about $30,000. US Bancorp DE acquired a new position in shares of AxoGen in the 4th quarter valued at $30,000. State of Wyoming bought a new stake in shares of AxoGen in the 4th quarter valued at $31,000. Fifth Third Bancorp acquired a new stake in AxoGen during the 1st quarter worth $92,000. Finally, Harvest Fund Management Co. Ltd bought a new position in AxoGen during the fourth quarter worth about $93,000. 80.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Erick Wayne Devinney sold 15,111 shares of the company's stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $17.50, for a total transaction of $264,442.50. Following the transaction, the insider now owns 217,762 shares of the company's stock, valued at $3,810,835. This represents a 6.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Amy Mcbride Wendell sold 5,000 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $20.02, for a total value of $100,100.00. Following the sale, the director now directly owns 97,899 shares of the company's stock, valued at $1,959,937.98. This represents a 4.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.00% of the stock is currently owned by corporate insiders.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.